Laser induced cavitation is one of the effective techniques to generate controlled cavitation bubbles, both for basic study and for applications in different fields of engineering and medicine. Unfortunately, control of bubble formation and symmetry is hardly achieved due to a series of concurrent causes. In particular, the need to focus the laser beam at the bubble formation spot leads, in general, to a conical region proximal to the light source where conditions are met for plasma breakdown. A finite sized region then exists where the electric field may fluctuate depending on several disturbing agents, leading to possible plasma fragmentation and plasma intensity variation. Such irregularities may induce asymmetry in the successive bubble dynamics, a mostly undesired effect if reproducible conditions are sought for. In the present paper, the structure of the breakdown plasma and the ensuing bubble dynamics are analyzed by means of high speed imaging and intensity measurements of the shockwave system launched at breakdown. It is found that the parameters of the system can be tuned to optimize repeatability and sphericity. In particular, symmetric rebound dynamics is achieved almost deterministically when a pointlike plasma is generated at the breakdown threshold energy. Spherical symmetry is also favored by a large focusing angle combined with a relatively large pulse energy, a process which, however, retains a significant level of stochasticity. Outside these special conditions, the elongated and often fragmented conical plasma shape is found to be correlated with anisotropic and multiple breakdown shockwave emission.

We report on the use of one-dimensional photonic crystals to detect clinically relevant concentrations of ERBB2/neu/Her2 in cell lysates. ERBB2 is a pivotal breast cancer biomarker and targetable oncogenic driver associated with aggressive breast cancer subtypes. To quantitate soluble ERBB2, we developed an optical platform that combines label-free and fluorescence detection modes. Such platform makes use of a sandwich assay in which the one-dimensional photonic crystals sustaining Bloch surface waves are tailored with a monoclonal antibody for highly specific biological recognition (BSW biochip). In a second step, a second antibody to ERBB2 quantitatively detects the bound analyte. The strategy of the present approach takes advantage of the combination of label-free and fluorescence techniques, making bio-recognition more robust and sensitive. In the fluorescence operation mode, the platform can attain the limit of detection 0.3ng/mL (1.5pM) for ERBB2 in cell lysates. Such resolution meets the international guidelines and recommendations (15ng/mL) for diagnostic ERBB2 assays that in the future may help to more precisely assign therapies counteracting cancer cell proliferation and metastatic spread.

We describe the design and fabrication of biochips based on 1-D photonic crystals supporting Bloch surface waves for label-free optical biosensing. The optical properties of Bloch surface waves are studied in relation to the geometry of the photonic crystals and on the properties of the dielectric materials used for the fabrication. The planar stacks of the biochips are composed of silica, tantala, and titania that were deposited using plasma-ion-assisted evaporation under high-vacuum conditions. The biochip surfaces were functionalized by silanization, and appropriate fluidic cells were designed to operate in an automated platform. An angularly resolved ellipsometric optical sensing apparatus was assembled to carry out the sensing studies. The angular operation is obtained by a focused laser beam at a fixed wavelength and detection of the angular reflectance spectrum by means of an array detector. The results of the experimental characterization of the physical properties of the fabricated biochips show that their characteristics, in terms of sensitivity and figure of merit, match those expected from the numerical simulations. Practical application of the sensor was demonstrated by detecting a specific glycoprotein, Angio-poietin 2, that is involved in angiogenesis and inflammation processes. The protocol used for the label-free detection of Angiopoietin 2 is described, and the results of an exemplary assay, carried out at a relatively high concentration of 1 μg/ml, are given and confirm that an efficient detection can be achieved. The limit of detection of the biochips for Angiopoietin 2, based on the protocol used, is 1.5 pg/mm2 in buffer solution. The efficiency of the label-free assay is confirmed by independent measurements carried out by means of confocal fluorescence microscopy